atriclip seal deal
report revenu better street-
high forecast primari driver upsid vs model stronger
atriclip result atriclip volum remain solid slight boost
premium price flex meanwhil open surgeri sale
in-lin better result offset softer ou sale stabil
open-surgeri result remain encourag enhanc confid
revis guidanc remain achiev
beatabl expect earn beat posit receiv
morn trade share frankli miss run low
think quarterli beat possibl share
consider run last year may see meaning
catalyst converg data read-out time
feel share current valuat ntm sale fair consid
growth profil vs fast-grow med-tech peer
maintain neutral rate
china back track without disclos specif manag
comment saw solid initi order china quarter
vs lack sale last quarter compani also note
process pursu addit approv chines market
next sever year addit manag experienc good
traction part western europ
atriclip product iter open new opportun
manag indic flex lead
opportun new account particular flex
attract physician previous hesit use procedur
cabg case largest segment concomit procedur
broadli devic adopt also buoy favor societi
guidelin greater awar
valuat rate neutral risk found page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
 revenu increas y/i open surgeri growth driven
princip cryo product sale mi result good
traction epi-sens offset declin legaci mi sale fusion
appendag manag growth volum strength
supplement premium price flex look ou
result overal revenu increas constant currenc basi drien
sale asia western european market expect china rebound
initi solid order via atrc new chines distributor quarter
sale
gross margin strong quarter vs result
mix manag cite high volum capit equip
intern market spend percentag revenu
better forecast final sg expens well forecast
despit increas legal cost train addit headcount sg
quarter also benefit non-cash credit relat chang
converg conting consider liabil told adjust ebitda
vs forecast loss
actualsbtig estimate varianceww open-heart mi appendag valv tax ebitda margin incom btig estim compani adj ebitda margin exclud stock-bas comp item varianc
incorpor result model chang includ rais
 atriclip revenu beyond feel procedur
price growth sustain trim mi ablat
revenu slightli increas revenu forecast
maintain gross margin estim toward higher end
rang make signific chang expens item though
admit sg could trend higher depend scope doj
rate neutral ev-to-sal basi share trade
next twelv month estim though investor interest may heighten
near converg data encourag consist open
surgeri result feel share fairli valu consid
compani revenu growth absenc materi catalyst trial
data releas btig provid price target neutral-r stock
risk rate includ trial data success physician train surgic
procedur salesforc product open-heart surgeri volum fda
volatil ou result share shift away surgic ablat procedur
litig
exhibit comp tabl fast-grow med-tech compani
revenu growth ebitda ep btig estim compani ebitda margin exclud stock-bas comp item newold changentm inc ingnnot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
atricur incom research gener expens incom pre-tax incom tax net incom dilut ep share net incom tax expens incom amort compens adjust ebitda margin y/i chang analysi good research gener net incom tax btig estim compani report
statesest open-heart procedur open-heart ablat ablat mi procedur mi asp invas ablat atriclip procedur atriclip asp ablat tool unit open-heart procedur ou open-heart ablat ablat mi procedur ou mi ablat atriclip procedur ou atriclip ablat atriclip tool btig estim compani provid dollar revenu per segment procedur price detail present model estim base compani commentari
btig cover compani mention report
appendix analyst certif import disclosur
